Aurobindo-Sandoz End $1bn US Deal

Trade Clearance Not Forthcoming

Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.

Footsteps_Arrows
Sandoz, Aurobindo Go Separate Ways • Source: Shutterstock

Aurobindo Pharma Ltd. and Novartis AG have called off their 2018 deal under which the Indian firm had snapped up Sandoz International GMBH’s US generic oral solids and dermatology businesses in a transaction worth around $1bn.

The decision, both parties said, was taken as US Federal Trade Commission clearance was not obtained within anticipated timelines.

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip